Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KNTE

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

Kinnate Biopharma logo

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Advanced Chart

Key Stats

Today's Range
$2.65
$2.65
50-Day Range
$2.45
$2.66
52-Week Range
$1.04
$7.18
Volume
N/A
Average Volume
418,678 shs
Market Capitalization
$125.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

KNTE Stock News Headlines

Kinetic Engineering Ltd (KNTE)
KNTE Kinnate Biopharma Inc.
Missed Nvidia? Trump’s Trade War Could Create a Bigger Winner
Missed out on Nvidia? Don’t worry — a bigger AI opportunity may be emerging right now, thanks to Trump’s newly announced tariffs. One under-the-radar U.S. semiconductor stock just gained a major edge over its foreign rivals. With demand poised to skyrocket, this chipmaker could be perfectly positioned to ride the next wave of AI growth. Shares are still flying low — but not for long.
See More Headlines

KNTE Stock Analysis - Frequently Asked Questions

Kinnate Biopharma Inc. (NASDAQ:KNTE) issued its earnings results on Thursday, May, 11th. The company reported ($0.73) EPS for the quarter, hitting analysts' consensus estimates of ($0.73).

Kinnate Biopharma (KNTE) raised $170 million in an initial public offering on Thursday, December 3rd 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kinnate Biopharma investors own include NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Canopy Growth (CGC) and DraftKings (DKNG).

Company Calendar

Last Earnings
5/11/2023
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$116.27 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.06 per share
Price / Book
0.52

Miscellaneous

Free Float
27,532,000
Market Cap
$125.13 million
Optionable
Optionable
Beta
1.38
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:KNTE) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners